Multisociety (AATS, ACCF, SCAI, and STS) expert consensus statement: Operator and institutional requirements for transcatheter valve repair and replacement, part 1: Transcatheter aortic valve replacement

TY - JOUR

T1 - Multisociety (AATS, ACCF, SCAI, and STS) expert consensus statement

T2 - Operator and institutional requirements for transcatheter valve repair and replacement, part 1: Transcatheter aortic valve replacement

AU - Tommaso, Carl L.

AU - Bolman, R. Morton

AU - Feldman, Ted

AU - Bavaria, Joseph

AU - Acker, Michael A.

AU - Aldea, Gabriel

AU - Cameron, Duke E.

AU - Dean, Larry S.

AU - Fullerton, Dave

AU - Hijazi, Ziyad M.

AU - Horlick, Eric

AU - Miller, D. Craig

AU - Moon, Marc R.

AU - Ringel, Richard

AU - Ruiz, Carlos E.

AU - Trento, Alfredo

AU - Weiner, Bonnie H.

AU - Zahn, Evan M.

N1 - Funding Information: The granting of staff privileges to physicians is an important mechanism to ensure quality care. The Joint Commission on Accreditation of Healthcare Organizations requires that medical staff privileges be based on professional criteria specified in medical staff bylaws. Physicians are charged with defining the criteria that constitute professional competence and with evaluating their peers accordingly. With the evolution of transcatheter aortic valve replacement (TAVR), an important opportunity arises for both cardiologists and surgeons to come together to identify the criteria for performing these procedures. The Society for Cardiovascular Angiography and Interventions (SCAI), American Association for Thoracic Surgery (AATS), American College of Cardiology Foundation (ACCF), and the Society of Thoracic Surgeons (STS) have, therefore, joined together to provide recommendations for institutions to assess their potential for instituting and/or maintaining a transcatheter valve program. This article concerns TAVR. As TAVR is in its infancy, there are few data on which to base this consensus statement. Therefore, many of these recommendations are based on expert consensus. As the procedures evolve, technology changes, experience grows, and more data is accumulated, there will certainly be a need to update this consensus statement. However, with the Food and Drug Administration (FDA) having just approved the first generation of TAVR devices, the writing committee and participating societies believe that the recommendations listed in this report serve as an appropriate starting point. In some ways, these recommendations apply to institutions more than to individuals. As there is a strong consensus that these new valve therapies are best performed using a team approach, these credentialing criteria may be best applied at the institutional level. Partnering societies used the ACCF’s policy on relationships with industry and other entities (RWI) to author this document ( http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx ). To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing committee, as well as peer reviewers of the document, were asked to disclose all current health care–related relationships, including those existing 12 months before initiation of the writing effort. A committee of interventional cardiologists and surgeons was formed to include a majority of members with no relevant RWI, and be led by an interventional cardiology co-chair and a surgical co-chair with no relevant RWI. Authors with relevant RWI were not permitted to draft or vote on text or recommendations pertaining to their RWI. RWI were reviewed on all conference calls and updated as changes occurred. Author and peer reviewer RWI pertinent to this document are disclosed in Appendices E1 and E2 , respectively. In addition, to ensure complete transparency, authors’ comprehensive disclosure information (including RWI not pertinent to this document) is available as an online supplement to this document. The work of the writing committee was supported exclusively by the partnering societies without commercial support. Writing committee members volunteered their time to this effort. Conference calls of the writing committee were confidential and attended only by committee members. SCAI, AATS, ACCF, and STS believe that adherence to these recommendations will maximize the chances that these therapies will become a successful part of the armamentarium for treating valvular heart disease in the United States. In addition, these recommendations will hopefully facilitate optimum quality during the delivery of this therapy, which will be important to the development and successful implementation of future, less invasive approaches to structural heart disease.

PY - 2012/6

Y1 - 2012/6

UR - http://www.scopus.com/inward/record.url?scp=84861155766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861155766&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2012.03.002

DO - 10.1016/j.jtcvs.2012.03.002

M3 - Article

C2 - 22595626

AN - SCOPUS:84861155766

SN - 0022-5223

VL - 143

SP - 1254-1263.e9

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

IS - 6

ER -